Human umbilical cord tissue-derived mesenchymal stromal cells attenuate remodeling after myocardial infarction by proangiogenic, antiapoptotic, and endogenous cell-activation mechanisms.

Abstract

INTRODUCTION:

Among the plethora of cells under investigation to restore a functional myocardium, mesenchymal stromal cells (MSCs) have been granted considerable interest. However, whereas the beneficial effects of bone marrow MSCs (BM-MSCs) in the context of the diseased heart are widely reported, data are still scarce on MSCs from the umbilical cord matrix (UCM-MSCs). Herein we report on the effect of UCM-MSC transplantation to the infarcted murine heart, seconded by the dissection of the molecular mechanisms at play.

METHODS:

Human umbilical cord tissue-derived MSCs (UCX®), obtained by using a proprietary technology developed by ECBio, were delivered via intramyocardial injection to C57BL/6 females subjected to permanent ligation of the left descending coronary artery. Moreover, medium produced by cultured UCX® preconditioned under normoxia (CM) or hypoxia (CMH) was collected for subsequent in vitro assays.

RESULTS:

Evaluation of the effects upon intramyocardial transplantation shows that UCX® preserved cardiac function and attenuated cardiac remodeling subsequent to myocardial infarction (MI). UCX® further led to increased capillary density and decreased apoptosis in the injured tissue. In vitro, UCX®-conditioned medium displayed (a) proangiogenic activity by promoting the formation of capillary-like structures by human umbilical vein endothelial cells (HUVECs), and (b) antiapoptotic activity in HL-1 cardiomyocytes subjected to hypoxia. Moreover, in adult murine cardiac Sca-1+ progenitor cells (CPCs), conditioned medium enhanced mitogenic activity while activating a gene program characteristic of cardiomyogenic differentiation.

CONCLUSIONS:

UCX® preserve cardiac function after intramyocardial transplantation in a MI murine model. The cardioprotective effects of UCX® were attributed to paracrine mechanisms that appear to enhance angiogenesis, limit the extent of the apoptosis, augment proliferation, and activate a pool of resident CPCs. Overall, these results suggest that UCX® should be considered an alternative cell source when designing new therapeutic approaches to treat MI.

• Authors: Diana Santos Nascimento, Diogo Mosqueira, Luís Moura Sousa, Mariana Teixeira, Mariana Filipe, Tatiana Pinho Resende, Ana Francisca Araújo, Mariana Valente, Joana Almeida, José Paulo Martins, Jorge Miguel Santos, Rita Nogueira Bárcia, Pedro Cruz, Helder Cruz, Perpétua Pinto-do-Ó
• Journal: Stem cell research & therapy (Stem Cell Res Ther) Vol. 5 Issue 1 Pg. 5 (Jan 10 2014) ISSN: 1757-6512 [Electronic] England
• PMID: 24411922 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Topics

• Animals
• Apoptosis
• Cell Differentiation
• Cell Line
• Cell Proliferation
• Cells, Cultured
• Female
• Fetal Blood (cytology)
• Human Umbilical Vein Endothelial Cells (cytology, physiology)
• Humans
• Mesenchymal Stem Cell Transplantation
• Mesenchymal Stem Cells (cytology, physiology)
• Mice
• Mice, Inbred C57BL
• Myocardial Infarction (therapy)
• Myocytes, Cardiac (cytology, physiology)
• Neovascularization, Physiologic
• Paracrine Communication
• Ventricular Remodeling